Prometa Pharmacotherapy for Methamphetamine Dependence
Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy of the PROMETA pharmacotherapy compared
to placebo for initiating abstinence and for preventing relapse to methamphetamine use in
treatment-seeking individuals meeting criteria for methamphetamine abuse. It is hypothesized
that individuals assigned to receive the PROMETA pharmacotherapy, compared to placebo, will
demonstrate significantly fewer and less intense withdrawal symptoms, more days abstinent
from methamphetamine use, and fewer relapses to methamphetamine use as assessed by
self-report of drug use verified by urine samples.